AbbVie Says 20% Of U.S. Managed Care Lives Covered Exclusively By Viekira Pak
This article was originally published in The Pink Sheet Daily
Executive Summary
Formulary decisions for HCV agents are occurring rapidly since Viekira’s approval, with AbbVie saying it currently has access to about 40% of U.S. managed care lives. Gilead and AbbVie likely will take patients from each other’s exclusive formulary positions, however, due to labeling differences for Harvoni and Viekira.